meports.com

What it is

Meports positions itself as “Patient Intelligence Infrastructure,” primarily serving GLP-1 telehealth platforms. It aims to solve the lack of continuous patient status visibility between monthly follow-ups: patients wear devices such as Apple Watch, Oura, Fitbit, WHOOP, and Garmin in daily life, while Meports standardizes passive data such as HR, HRV, sleep, activity, and SpO2, then turns it into signals usable for clinical and operational workflows.

Core capabilities

The product centers on a white-label SDK, device OAuth connections, cross-device data standardization, Webhook/REST API signal delivery, population analytics dashboards, patient summary views for clinical staff, and an optional white-label patient progress dashboard. Its key signals include titration readiness, early side-effect detection, churn risk prediction, and proxy monitoring for lean mass loss. For GLP-1 platforms, these capabilities can be embedded into an existing patient App and used to push signals into an EHR or care dashboard.

Pricing and integration

The page does not publish specific pricing. It only states that pricing is charged per patient per month and that access must be requested; integration documentation and pricing will be sent within 48 hours. The official claim is “Live in a week, not a quarter,” but this still needs to be validated against the target platform’s existing App, EHR, and data compliance processes. The product is currently in early access/initial pilot, with limited pilot slots available.

Security and compliance

Meports discloses that it is HIPAA compliant, provides a BAA, encrypts PHI at rest and in transit, and is undergoing SOC 2. For a healthcare SaaS product, these are necessary fundamentals. However, the page does not disclose more detailed information on audit status, data residency, permission models, incident response, or clinical validation of its algorithms.

Pros, cons, and who it is for

Its advantages are a focused vertical use case, white-label integration friendliness, coverage of mainstream wearable devices, and reduced manual logging burden for patients through passive collection. The downsides are limited information on pricing, customer cases, algorithm effectiveness, and product maturity, while SOC 2 has not yet been completed. It is better suited to U.S. digital health platforms that already have a meaningful GLP-1 patient base and want to improve retention and follow-up quality.

Access from China and alternatives

Access from China is unknown, and the product is clearly designed around the U.S. HIPAA, BAA, and GLP-1 telehealth market. Payment methods are not disclosed. For deployment in China, key areas to evaluate include cross-border data transfer, wearable device coverage, medical compliance, and local EHR integration. Comparable options include Validic, Terra API, Human API, and Healthie; in China, solutions such as 妙健康 and 乐心医疗开放平台 may also be worth watching.